ACAD Q4 2024 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$260M+12.4% YoY

Gross Profit

$238M91.6% margin

Operating Income

$154M59.1% margin

Net Income

$144M55.4% margin

EPS (Diluted)

$0.86

QoQ Revenue Growth

+3.7%

Cash Flow

Operating Cash Flow

$40M

Free Cash Flow

$40M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$455M

Stockholders' Equity

$733M

Cash & Equivalents

$320M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$260M	$231M	+12.4%
Gross Profit	$238M	$213M	+11.6%
Operating Income	$154M	$35M	+339.3%
Net Income	$144M	$46M	+213.9%